IO Biotech hits 225-patient enrollment milestone in Phase 3 melanoma trial; expanded to 380

IO Biotech, Inc.

225 patients randomized in Phase 3 trial of IO102-IO103 + pembrolizumab for advanced melanoma.
Interim ORR analysis now triggered; positive data could enable BLA for accelerated approval in U.S.
Trial enrollment increased to 380 patients to potentially accelerate primary PFS endpoint.
Company expects full enrollment by year-end 2023; cash runway through Q3 2024.
CEO notes potential first vaccine approval in 2025 if interim analysis is positive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.